RxDoctor Payments Data

Javier Parra, MD

Gastroenterology · Miami, FLNPI 1194764399

Payments from drug & device makers

$68,363in general payments, 2019–2025

Across 180 payments — averaging $379.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Capsovision, Inc.$60K
  • Pentax Of America, Inc.$5K
  • AbbVie$1K
  • Johnson & Johnson$527
  • Medtronic$515
  • QOL Medical, LLC$266
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$60,64489%
  • Speaking & faculty fees$1,5002%
  • Travel & lodging$1,9613%
  • Food & beverage$4,0746%
  • Education$1840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,363 in reported general payments places this provider in the 85th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$160,975
Medicare patients
365
Services billed
3,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HumiraAdalimumab13$86,180
LinzessLinaclotide38$26,200
ClenpiqSod Picosulf/Mag Ox/Citric Ac92$15,877
Dexlansoprazole DrDexlansoprazole13$5,150
Sucralfate26$4,923
CholestyramineCholestyramine (With Sugar)20$3,142
Omeprazole166$3,105
Ondansetron Hcl13$1,917
Dicyclomine Hcl57$1,396
Famotidine75$1,244
Pantoprazole Sodium65$795
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates12$756
Esomeprazole Magnesium12$406
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl18$285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Linzess$1,001$112,38151 claims
Ferring Pharmaceuticals Inc.Clenpiq$84$15,87792 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →